Sulzer Medica on upward trend
This article was originally published in Clinica
Sulzer Medica plans to continue the growth of last year through product developments and acquisitions. The company's "dual strategy" has been facilitated through the company's partial flotation in Switzerland and the US last summer, which raised over $500 million. It is possible that its parent company Sulzer may sell off a second share of its subsidiary, Sulzer Medica to raise additional funds.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.